Evidence map›Paper›PMID 41393216›Full record

ArticleEJHaem2025

Successful Birth After First-Trimester Ravulizumab Exposure in a Patient With Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

Tatsuki Morioka, Shoya Arai, Yumi Arai, Satoshi Konno, Katsuhiro Tokuda, Takuji Matsuo, Kensuke Matsumoto, Ryosuke Shirasaki, Jun Ooi, Chikara Kihira and 3 more

Abstract read
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tatsuki MoriokaDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Shoya AraiDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Yumi AraiDepartment of Obstetrics and Gynecology Teikyo University School of Medicine Tokyo Japan.
Satoshi KonnoDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Katsuhiro TokudaDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Takuji MatsuoDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Kensuke MatsumotoDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Ryosuke ShirasakiDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.
Jun OoiDepartment of Clinical Laboratory Science Teikyo University Tokyo Japan.
Chikara KihiraDepartment of Obstetrics and Gynecology Teikyo University School of Medicine Tokyo Japan.
Yukifumi SasamoriDepartment of Obstetrics and Gynecology Teikyo University School of Medicine Tokyo Japan.
Kazunori NagasakaDepartment of Obstetrics and Gynecology Teikyo University School of Medicine Tokyo Japan.
Haruko TashiroDepartment of Hematology/Oncology Teikyo University School of Medicine Tokyo Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disorder treated with complement C5 inhibitors. While eculizumab (Ecu) has documented safety in pregnancy, data on ravulizumab (Rav) are scarce. We report a 25-year-old woman with PNH who experienced inadvertent Rav exposure at 8 weeks of pregnancy before switching to Ecu. Despite requiring transfusions, she delivered a healthy infant at term without anomalies or thrombosis. This case represents one of the earliest reports of Rav use in pregnancy, suggesting potential safety. Further data are needed, and multidisciplinary management remains essential for pregnant patients with PNH. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Indexed as

case reportcomplement inhibitoreculizumabparoxysmal nocturnal hemoglobinuriapregnancyravulizumab

Identifiers

PMID41393216
PMCPMC12698932

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.